Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Exosomes are small extracellular vesicles released by almost all cell types in physiological and pathological conditions. The exosomal potential to unravel disease mechanisms, or to be used as a source of biomarkers, is being explored, in particularly in the field of neurodegenerative diseases. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in the world and exosomes appear to have a relevant role in disease pathogenesis. This review summarizes the current knowledge on exosome contributions to AD as well as their use as disease biomarker resources or therapeutic targets. The most recent findings with respect to both protein and miRNA biomarker candidates for AD, herein described, highlight the state of the art in this field and encourage the use of exosomes derived from biofluids in clinical practice in the near future. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ngolab, J., Trinh, I., Rockenstein, E., Mante, M., Florio, J., Trejo, M., Masliah, D., Adame, A., Masliah, E., & Rissman, R. A. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0445-5 · Cited by 200
RetractedBiogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 1×
“The promising therapeutic potential of exosomes in AD is enhanced by the fact that exosomes can cross the blood–brain barrier (Alvarez-Erviti et al., 2011; Haney et al., 2015; Yang et al., 2015).”
BackgroundThe neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 2×
“Tau proteins belong to the family of microtubule-associated proteins and phosphorylation is a key event in the regulation of the interaction between Tau and microtubules (DeTure & Dickson, 2019).”
BackgroundBlennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 1×
“The process involves phagocytizing Tau and then secreting it into exosomes, potentially representing a new mechanism for Tau transport that explains non-synaptic propagation (Asai et al., 2015).”
BackgroundAlzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025
Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 1×
“This miRNA levels were decreased in the hippocampus, temporal cortex and CSF of AD individuals (Cogswell et al., 2008; McKeever et al., 2018; Takousis et al., 2019; Villela et al., 2016).”
BackgroundNeurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyte–Neuron Communication
Frühbeis, C., Fröhlich, D., Kuo, W. P., Amphornrat, J., Thilemann, S., Saab, A. S., Kirchhoff, F., Möbius, W., Goebbels, S., Nave, K.-A., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001604 · Cited by 902
Zhang, Y., Chopp, M., Meng, Y., Katakowski, M., Xin, H., Mahmood, A., & Xiong, Y. (2015) · Journal of neurosurgery · doi:10.3171/2014.11.jns14770 · Cited by 737
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · cited 1×
“Blood-based biomarkers can represent an interesting alternative to AD diagnosis since these would be less invasive, easy to implement and a cost-effective alternative (Hampel et al., 2018; Zetterberg, 2018).”
BackgroundTakahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706
The release and trans-synaptic transmission of Tau via exosomes
Wang, Y., Balaji, V., Kaniyappan, S., Krüger, L., Irsen, S., Tepper, K., Chandupatla, R., Maetzler, W., Schneider, A., Mandelkow, E., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0143-y · Cited by 674
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552 · cited 6×
“…McKeever et al. (2018) miR−125b−5p# APP - McKeever et al. (2018) miR−132−5p nf nf Gui, Liu, Zhang, Lv, and Hu (2015) miR−145−5p ADAM17; APH1A CAPN2; GSK3β McKeever et al. (2018) miR−485−5p nf nf Gui et al. (2015) ↓ miR−16–2 nf nf Gui et al. (2015) miR−16−5p ADAM10; APH1A; APP; MME CDK5R1 McKeever…”
InfluentialAlzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527
Dinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., & Bieberich, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.012 · Cited by 494
Cheng, L., Doecke, J. D., Sharples, R. A., Villemagne, V. L., Fowler, C. J., Rembach, A., Martins, R. N., Rowe, C. C., Macaulay, S. L., Masters, C. L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.127 · Cited by 409
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400 · cited 1×
“Lysosomal dysfunction is another AD feature related to APP impaired metabolism that probably precedes AD pathogenesis (Nixon, 2017).”
Backgroundη-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398 · cited 1×
“The two main pathways by which APP can be processed are the non-amyloidogenic and the amyloidogenic pathways, although more recently an additional pathway has been proposed (Willem et al., 2015).”
BackgroundWang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2019) · Nanoscale · doi:10.1039/c9nr01255a · Cited by 324
Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons
Goldie, B. J., Dun, M. D., Lin, M., Smith, N. D., Verrills, N. M., Dayas, C. V., & Cairns, M. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku594 · Cited by 318
Genes and pathways underlying regional and cell type changes in Alzheimer’s disease
Miller, J. A., Woltjer, R. L., Goodenbour, J. M., Horvath, S., & Geschwind, D. H. (2013) · Genome Medicine · doi:10.1186/gm452 · Cited by 275
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Reza-Zaldivar, E. E., Hernández-Sapiéns, M. A., Gutiérrez-Mercado, Y. K., Sandoval-Ávila, S., Gomez-Pinedo, U., Márquez-Aguirre, A. L., Vázquez-Méndez, E., Padilla-Camberos, E., & Canales-Aguirre, A. A. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.255978 · Cited by 256
Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
Lim, C. Z. J., Zhang, Y., Chen, Y., Zhao, H., Stephenson, M. C., Ho, N. R. Y., Chen, Y., Chung, J., Reilhac, A., Loh, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09030-2 · Cited by 209
BIN1 favors the spreading of Tau via extracellular vesicles
Crotti, A., Sait, H. R., McAvoy, K. M., Estrada, K., Ergun, A., Szak, S., Marsh, G., Jandreski, L., Peterson, M., Reynolds, T. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45676-0 · Cited by 171 · cited 1×
“Additionally, the spreading of Tau by microglia-derived exosomes could be decreased in in vitro and in vivo models through genetic depletion of BIN1, that is one of the major genetic locus associated with late onset AD (Crotti et al. 2019).”
BackgroundCombined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129
Eitan, E., Hutchison, E. R., Marosi, K., Comotto, J., Mustapic, M., Nigam, S. M., Suire, C., Maharana, C., Jicha, G. A., Liu, D., et al. (2016) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2016.19 · Cited by 129
Apolipoprotein E4 genotype compromises brain exosome production
Peng, K. Y., Pérez-González, R., Alldred, M. J., Goulbourne, C. N., Morales-Corraliza, J., Saito, M., Saito, M., Ginsberg, S. D., Mathews, P. M., & Levy, E. (2019) · Brain · doi:10.1093/brain/awy289 · Cited by 109
Fernandes, A., Ribeiro, A. R., Monteiro, M., Garcia, G., Vaz, A. R., & Brites, D. (2018) · Biochimie · doi:10.1016/j.biochi.2018.05.015 · Cited by 93 · cited 1×
“This observation suggested that miR-21 can be an exosomal biomarker of microglia activation, enhancing the importance of these vesicles for the neuronal-microglial communication (Fernandes et al., 2018).”
BackgroundAβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A
Willén, K., Edgar, J. R., Hasegawa, T., Tanaka, N., Futter, C. E., & Gouras, G. K. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0203-y · Cited by 86
Cited by
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P.-C., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 257
Clinical Applications of Exosomes: A Critical Review
Lee, K. W. A., Chan, L. K. W., Hung, L. C., Phoebe, L. K. W., Park, Y., & Yi, K.-H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147794 · Cited by 127
Song, S., Lee, J. U., Jeon, M. J., Kim, S., & Sim, S. J. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113864 · Cited by 88
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910794 · Cited by 81
“Further, defective hyperphosphorylation and misfolded tau proteins yield intracellular NFTs and impair signaling across the neurons [6].”
BackgroundAltered Extracellular Vesicle miRNA Profile in Prodromal Alzheimer’s Disease
Visconte, C., Fenoglio, C., Serpente, M., Muti, P., Sacconi, A., Rigoni, M., Arighi, A., Borracci, V., Arcaro, M., Arosio, B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914749 · Cited by 57
Metadata
- Authors
- Soares Martins, T., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., da Cruz e Silva, O. A. B., & Henriques, A. G.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2020-08-06
- Volume
- 156
- Issue
- 2
- Pages
- 162-181
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W3039306930
- Cited by
- 174
- References
- 38
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.